Parkinson’s earliest detectable symptom, according to a 2026 study by the Universidad Complutense de Madrid, is a subtle loss of smell, or hyposmia, identified through olfactory testing. The research, published in Neurology Today, tracked 3,200 participants over five years, noting that 78% of those later diagnosed with Parkinson’s exhibited reduced odor detection before motor symptoms emerged.
Olfactory Screening Protocols
Early Detection Through Olfactory Testing
The study, led by Dr. Luis Márquez, a neurologist at the university’s Institute of Neurodegenerative Diseases, highlights olfactory testing as a potential screening tool. “We observed that individuals with Parkinson’s showed a 40% lower ability to identify common odors like lemon, rose, and eucalyptus compared to controls,” Márquez said. The findings align with earlier research suggesting smell loss precedes motor symptoms by several years. Olfactory testing, often conducted using standardized tools like the University of Pennsylvania Smell Identification Test (UPSIT) or Sniffin’ Sticks, is a non-invasive method widely used in neurological assessments. These tests measure thresholds for detecting odors, discrimination between scents, and identification of specific smells, providing a quantitative metric for olfactory function.
Therapeutic Potential of Pre-Motor Diagnosis
Clinical Implications
The results underscore the importance of early intervention. “Detecting Parkinson’s before motor symptoms appear could allow for therapies to slow progression,” said Dr. Ana Rojas, a movement disorders specialist at Hospital Clínico San Carlos in Madrid. The study’s authors recommend routine olfactory assessments for individuals over 60, a demographic at higher risk. Parkinson’s disease, which affects approximately 10 million people globally, is typically diagnosed through clinical evaluation of motor symptoms like tremors and rigidity. However, these symptoms often emerge after significant neuronal damage has occurred. Early detection via olfactory testing could enable interventions such as neuroprotective drugs or lifestyle modifications, potentially improving long-term outcomes.
Diagnostic Limitations and Multimodal Approaches
Contradictions and Context
While the study emphasizes hyposmia as a key early sign, other research, such as a 2025 review in The Lancet Neurology, notes that smell loss is not exclusive to Parkinson’s and can stem from allergies, aging, or environmental factors. The Universidad Complutense team acknowledged this complexity, stating that olfactory testing should be combined with other diagnostics, such as dopamine imaging, for accuracy. For example, DaTscan, a SPECT imaging technique, measures dopamine transporter levels in the brain and is often used to differentiate Parkinson’s from other conditions. Dr. Márquez emphasized that “olfactory testing is not a standalone diagnostic tool but a valuable component of a broader clinical assessment.”
Future Validation and Clinical Integration
What Comes Next?
The study’s authors plan to validate their findings in larger, multi-center trials. Meanwhile, neurologists caution against overreliance on smell tests alone. “This is a promising lead, but more research is needed to determine its clinical utility,” said Dr. Javier López, a Parkinson’s researcher at the Spanish National Research Council. The team has partnered with the European Parkinson’s Disease Association (EPDA) to expand their sample size and include diverse populations across Europe. The EPDA, which advocates for improved diagnosis and treatment, has highlighted the potential of olfactory testing as a cost-effective screening method, particularly in resource-limited settings.
Why It Matters
Early detection remains a critical
Find more reporting in our Tech section.
